1 Those who attend screening have a 25% reduction (RR 0.75, CI = 0.66 to 0.84) in their risk of death, but only 40% return all three BCSP gFOB kits, although involving GPs in screening increases uptake.
BaCkground and advantages over exIstIng teCHnology
A variety of home-use faecal occult blood testing (FOBt) kits remain commercially available to UK patients despite caution regarding their safety and accuracy.
FOBt is a relatively non-invasive and inexpensive test. The NHS Bowel Cancer Screening Programme (BCSP) and the majority of European screening programmes uses guaiac FOBt (gFOB). A Cochrane Review has shown that biennial population screening with card-based postal laboratory-analysed gFOB can reduce colorectal mortality by 15% (relative risk [RR] 0.85, confidence interval [CI] = 0.78 to 0.92) in people aged 45-74 years. 1 Those who attend screening have a 25% reduction (RR 0.75, CI = 0.66 to 0.84) in their risk of death, but only 40% return all three BCSP gFOB kits, although involving GPs in screening increases uptake. 1, 2 Faecal immunochemical testing (FIT) measures the globin component of human haemoglobin. Unlike gFOB, FIT does not require dietary restriction, is specific to lower gastrointestinal (GI) cancers as upper GI enzymes degrade human globin, and is less affected by concomitant medication use. FIT has started to replace gFOB in some regions (for example, the Czech Republic and Italy) and guidelines (for example, the US) given these gains in diagnostic accuracy.
Home FIT kits are designed to obtain samples from multiple parts of a single stool and use immunochromatography to provide an immediate (qualitative) positive or negative result, avoiding the delay and costs associated with laboratory (quantitative) FIT and gFOB. Patients may present to primary care having used home bowel-testing kits, and so this report outlines the existing evidence detailing the potential accuracy and utility of the home FIT available to the adult consumer.
detaIls of teCHnology
Based on a search conducted in December 2013, Box 1 shows the CE approved FIT kits retailing to the UK consumer for between £5.59 and £15.95, marketed as stand-alone home-test kits for use on a single stool sample with rapid results. The PRIMA home test is included as a stand-alone test that is repeated on three samples. None of these kits currently has FDA approval.
PatIent grouP and use
Home-based testing of adult patients.
ImPortanCe
Colorectal cancer is the third most common cancer worldwide after lung and breast; incidence patterns are associated with family history and genetics, and variations in diet, deprivation, body weight, and physical activity. In the UK in 2010, colorectal cancer was the fourth most common cancer, accounting for 40 695 new cases and 10% of cancer-related deaths. Early detection of low-grade colorectal cancer increases the likelihood of curative surgical resection and survival, but systematic review repeatedly shows the predictive value of individual (or combined) symptoms or signs is limited in primary care. 3, 4 PrevIous researCH accuracy compared with existing technology No studies evaluating the diagnostic accuracy of any of the home bowel testing kits available to the UK consumer were found.
A systematic review of the value of symptoms and additional diagnostic tests for colorectal cancer detection in primary care reported that qualitative FIT was easy to perform and well tolerated for the investigation of colorectal cancer in symptomatic patients in primary care (sensitivity 50-100%, specificity 71-93%) if compared to gFOB (sensitivity 33-100%, specificity 72-94%). 3 However, five FIT kits the HemeSelect™ test, Hemoblot, iFOBT strip device, Immunohemostick, InSure ® FIT™ test) were compared in studies involving symptomatic patients referred to secondary care for investigation, and so no direct evidence was found from primary care populations. The studies included were highly heterogeneous, and validation of the findings using larger studies is needed in primary care, but subgroup analyses suggested that FIT was more sensitive for cancer at all sites and for detecting earlier-stage disease than gFOB. 3 One subsequent study was found evaluating an additional FIT (OC-Light 'Eiken', Nagase, Japan) in 112 symptomatic patients referred to a rapid-access colorectal service without overt rectal bleeding who underwent lower GI endoscopy or barium enema. For colorectal cancer the sensitivity was 100% and specificity 86.3%, positive predictive value 56.6%, and negative predictive value 100% (confidence intervals not reported). 5 It remains unclear whether this accuracy would remain if the test was used in primary care or at home.
Overall, no studies were found that evaluated the accuracy of qualitative FIT kits in asymptomatic patients at home. However, data available from laboratory (quantitative) FIT suggest that home testing may have a potential role in diagnosis, although confirmatory studies in primary care populations are required.
accuracy of laboratory fIt versus gfoB
A Dutch randomised controlled trial detected advanced neoplasia in a screening population at significantly higher rates using laboratory-based quantitative FIT (OR 2.4, 95% CI = 1.3 to 4.1) compared with laboratory-analysed gFOB, 6 and a large study of 85 149 average-risk individuals from the French colorectal cancer screening programme showed superior accuracy of automated quantitative FIT over manual laboratory-analysed gFOB. 7 Numerous diagnostic accuracy studies support that laboratory-based quantitative FIT has higher sensitivity and specificity when screening colorectal cancer than gFOB, especially for detecting high-risk adenomas. Tip of top is snapped off and two drops are dropped into the dropping hole of the test cassette and result given in 5 minutes.
PrIma

® Home test: Bowel test -foB
Unscrew the syringe cap and dip the stick about 2 cm into the faeces at three separate Not specified Healthy Europe s.r.l., Milan, Italy locations, replace the collection stick to the collection device and shake well repeating Distributed through Amazon.co.uk this procedure three times on separate stools keeping the device in the fridge in between. Snap off the tip and drop six drops to the sample well and read the result after 10 minutes seen with smaller lesions. Depending on the haemoglobin threshold used, up to two-thirds of advanced neoplasms can be missed by single or double FIT sampling. 10 Increasing sensitivity at the cost of specificity by lowering the threshold value used for a single FIT test (instead of improving specificity by using two or more samples) risks overburdening colonoscopy services.
If an appropriate threshold is chosen in relation to the population tested, singlesample FIT testing may perform as accurately as repeated sampling. Several studies have indicated that a single sample using 7.5 μg/l represents a good tradeoff between sensitivity and specificity, but great variation in (and poor reporting of) the thresholds used by manufacturers still remain a problem (Box 1).
Impact compared with existing technology
FOBt has greater uptake than flexible sigmoidoscopy in screened populations, and screening uptake is significantly higher using FIT compared with gFOB (RR 1.21, 95% CI = 1.09 to 1.33). 11 Despite greater convenience due to simplified test procedure, there is no clear evidence currently that home (qualitative) FIT would further improve screening uptake at a population level. FIT could alternatively be used as a second line to reduce false positives from borderline gFOB.
relevant guidelines
The UK 2005 NICE referral guidelines for suspected cancer do not recommend the use of FOBt, stating 'the sensitivity, specificity, and positive predictive values of FOBt are too low to make these tests helpful'. In contrast, the 2012 Ontario guideline for the Referral of Patients with Suspected Colorectal Cancer by Family Physicians and Other Primary Care Providers recommends the use of FOBt in patients with no active rectal bleeding but with unexplained signs and symptoms who do not meet criteria for urgent or semiurgent referral. The 2015 NICE update consultation document recommends gFOB in cases without rectal bleeding with: abdominal pain; weight loss; iron deficiency (<60 years); or a change in bowel habit (<60 years). FIT is not recommended due to insufficient primary care evidence.
European guidelines for quality assurance in colorectal cancer screening and diagnosis recommend FIT rather than gFOB for screening asymptomatic individuals, noting that positive tests must be followed up with colonoscopy given the low specificity for colorectal neoplasia.
What this technology adds
FIT is more accurate than gFOB for screening, and comparable diagnostic accuracy can be achieved between laboratory based and qualitative FITs (if attention is given to the thresholds used). FIT offers advantages of one-step, single stool, home sampling. GP recommended home FIT could improve screening yield and uptake (as this has worked for gFOB), and home testing could potentially be used as part of diagnostic evaluation in symptomatic patients, but studies in primary care are needed to confirm this. The lack of robust evidence on the comparative accuracy of home bowel testing kits and laboratory methods needs urgent attention in both the asymptomatic and symptomatic patients. For example, a diagnostic accuracy study comparing laboratory (quantitative) FIT with the available home (qualitative) FITs when used at home by patients and in primary care by a GP. At present there is not enough information to confidently say whether a patient who presents to primary care having performed a home test and received a negative (or positive) result should be reassured (or investigated).
methodology
Standardised methodology was applied in writing this report, using prioritisation criteria and a comprehensive, standardised search strategy, and critical appraisal (full details at www.madox.org). The search for this article was conducted in December 2013. 
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